School of Medicine


Showing 181-200 of 244 Results

  • Philip Grant

    Philip Grant

    Clinical Associate Professor, Medicine

    BioMy research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.

  • Teodor Grantcharov

    Teodor Grantcharov

    Professor of Surgery (General Surgery)

    BioDr. Teodor Grantcharov completed his surgical training at the University of Copenhagen, and a doctoral degree in Medical Sciences at the University of Aarhus in Denmark.
    Dr. Grantcharov is a Professor of Surgery at Stanford University and Associate Chief Quality Officer for Innovation and Safety at Stanford Healthcare.

    Prior to joining Stanford, Dr. Grantcharov was a Professor of Surgery at the University of Toronto and Keenan Chair in Surgery at St. Michael’s Hospital in Toronto. He was the Founder of the International Centre for Surgical Safety – a multidisciplinary group of visionary scientists with expertise in design, human factors, computer- and data science, and healthcare research. He previously held Canada Research Chair in Simulation and Surgical Safety and was awarded the Queen Elizabeth II diamond jubilee medal for his contributions to clinical research and patient safety in Canada. Dr. Grantcharov was awarded the honorary fellowship of the Imperial College in London, the honorary fellowships of the Bulgarian, Danish and Brazilian surgical societies, the Spinoza Chair in Surgery from the University of Amsterdam and multiple national and international awards for his contributions to surgical education and surgical safety.

    Dr. Grantcharov’s clinical interest is the area of minimally invasive surgery, while his academic focus is in the field of surgical innovation and patient safety. He has become internationally recognized as a leader in this area with his work on curriculum design, assessment of competence and impact of surgical performance on clinical outcomes. Dr. Grantcharov developed the surgical Black Box concept, which aims to transform the safety culture in medicine and introduce modern safety management systems in the high-risk operating room environment.

    Dr. Grantcharov has more than 220 peer-reviewed publications and more than 200 invited presentations in Europe, South- and North America. He holds several patents and is the Founder of Surgical Safety Technologies Inc – an academic startup that commercializes the OR Black Box platform. He sits on numerous committees with Surgical Professional Societies in North America and Europe.

  • Dita Gratzinger

    Dita Gratzinger

    Professor of Pathology

    Current Research and Scholarly InterestsI have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.

  • Edward Graves

    Edward Graves

    Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)

    Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.

  • Nathanael S. Gray

    Nathanael S. Gray

    Krishnan-Shah Family Professor

    BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
    Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
    In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
    In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
    These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.

  • Florette K. Gray Hazard

    Florette K. Gray Hazard

    Professor - University Medical Line, Pathology

    Current Research and Scholarly InterestsMy scholarly pursuits are primarily focused on the study of death and disease in the pediatric population. It is through this work that I am able to explore fundamental concepts of neoplasia, such as histogenesis and mutagenesis, while utilizing a variety of investigational techniques.

  • Carlos Greaves

    Carlos Greaves

    Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences

    BioBorn and raised in Caracas, Venezuela. Medical school at the Central University School of Medicine, where Internship was completed.
    Residency training at Stanford Medical School, Department of Psychiatry. Work in Community Mental health in Maui, Hawaii for 4 years.
    Work at the Veterans Administration in Palo Alto for 3 years. Currently in Private Practice and as consulting psychiatrist at the Vaden Student Health center at Stanford

  • Henry T. (Hank) Greely

    Henry T. (Hank) Greely

    Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics

    Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.

  • Sherril L. Green, DVM, PhD

    Sherril L. Green, DVM, PhD

    Professor of Comparative Medicine

    Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.

  • Tamar Green

    Tamar Green

    Assistant Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences)

    Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.

  • Harry B Greenberg

    Harry B Greenberg

    Joseph D. Grant Professor in the School of Medicine, Emeritus

    Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.

  • Peter Greenberg

    Peter Greenberg

    Professor of Medicine (Hematology), Emeritus

    Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.